Raymond has more than 30 years of investment and entrepreneurial experience in the US and China technology sector. Prior, Raymond was Founding Partner of Taishan Invest, the leading institutional angel fund in China. Earlier, he was also Managing Partner at Navi Capital Partners and a Venture Partner at Northern Light Venture Capital. Prior, Raymond was the CEO of Linktone (NASDAQ: LTON), the leading wireless value-added services provider in China, where he led the company through a turnaround situation and took the company public on NASDAQ in 2004. Before Linktone, Raymond was a senior executive and entrepreneur at several high-technology companies in Silicon Valley and China, including Founder and CEO of RivalWatch and Founder and CEO of Saratoga Technology Inc.

Raymond is a Delegate Member of the World Economic Forum Davos Global Agenda Council and a former Chairman of the prestigious Tsinghua University Entrepreneur and Executive Club (TEEC). Raymond serves on the Board of Directors for WSC portfolio company Unity Technologies and servers as an Observer at Couchbase and Mirantis. He also served as a former Board member for Maginatics (acquired by EMC in 2014) , and co-led the WestSummit's investment in Twitch, Ninebot and Ximalaya. Raymond holds a Bachelors from Tsinghua University and Masters from the Graduate School of China EPRI.

Mr. Palermo currently leads Aquedeon Medical Inc., a company developing a novel anastomosis device for cardiothoracic surgery. He is a veteran of the medical device industry with over 30 years of experience and a proven track record in positing start-up companies for commercialization and successful acquisition. His skills encompass venture fundraising, business development, strategic planning, product development and executive management of companies spanning several segments with diverse regulatory requirements.

Mr. Palermo has served as chief operating officer of Dextera Surgical, acting CEO of UlceRx Medical, Inc., and was also President and CEO of ReVascular Therapeutics (Acquired by Boston Scientific, 2011), and Director of Research and Development at INtegrated Vascular Systems (Acquired by Abbot Vascular, 2003). Mr. Palermo received his B.S. in Technical Management from New Hampshire College.

Dr. Mike (Ming) Mao is the Founder and President/CEO of Antagene Inc., Founder of United Bioresearch Inc., and also a professor/faculty in University of East-West medicine. Dr. Mao has more than 25 years of biotech industry entrepreneur experience starting from scientific research to biotech investment and management. Prior to founding Antagene Inc., Dr. Mao was the Director of Immunology Department at Gennemed Synthesis Inc., in where he started the company's monoclonal antibody, immunoassay kit and cell based assay capacity, and grown the company to a leading company in monoclonal service sector with a significant revenue growth. Prior, Dr. Mao served as a Staff Scientist at lgenex Inc., a clinical diagnostic reference lab, where he developed new immunoassay and molecular diagnostics for FDA approval. Prior to lgenex, he was a Team Leader/Principal Scientist at Sinogen Inc., and then Director of Research and Development at Genex Bioscience Inc.

Additionally, Dr. Mao was a NASD licensed investment advisor in Edward Jones Investments (investment Series 7 and S 63 licensed) specialized in biotech investment and analysis and had over 10M assets in his managment. Dr. Mao published more than 10 peer-reviewed articles in leading scientific journals including a first author in Cell journal. Dr. Mao earned his Ph.D. degree in Microbiology and Immunology, and completed his postdoctoral training both in Tufts university School of Medicine and Stanford University Medical School, and completed his MD from Tong-Ji Medical University.

Jack is the General Manger of Internal Market Business Unit at Mindray Bio-Medical Co.. Prior, he was former General Manager of TCL Medical Asia Pacific, Director of GE China Medical Marketing and Sales. Jack received his B.E. from Tsinghua University, M.S. from McGill University.

Sanjeev Saxena has 30+ years in creating and managing medical device & biotech companies. He has raised funds in excess of $70 million for his companies, had successful exits, and is currently a Board member and Vice Chairman of Texas Tech University Research Park. Sanjeev is the founder of Harae Dx, a cancer diagnostics. He has won several awards and has been recognized as one of the leading CEO in 2018 by Silicon Review News and also as among the 50 most impactful social innovators. He has also been a keynote speaker at various conference including the TiE 2017 Healthcare track and Healthcare senate 2018 in India the equivalent of a Ted Talk.